LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

LLY

1,138

-1.01%↓

JNJ

238.3

+0.36%↑

ABBV

225.39

-0.27%↓

UNH

406.62

-1.33%↓

MRK

118.27

-1.34%↓

Home・Stock List・10X Genomics Inc (Class A)

10X Genomics Inc (Class A)

Open

SectorHealthcare

29.34 -0.68

Buy Sell

Overview

Share price change

24h

Current

Min

29.16

Max

30.97

Key metrics
By Trading Economics
Income	2.8M -13M
Sales	-15M 151M
EPS	0.07
Profit margin	-8.93
Employees	1,178
EBITDA	2.5M -17M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	-19.91% downside

Dividends
By Dow Jones
Next Earnings	6 Aug 2026

Market Stats
By TradingEconomics
Market Cap	1.1B 3.9B
Previous open	30.02
Previous close	29.34

News Sentiment

By Acuity

50%

153 / 344 Healthcare

10X Genomics Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

9 Jun 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 Jun 2026, 23:45 UTC

Acquisitions, Mergers, Takeovers

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 Jun 2026, 23:44 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 Jun 2026, 23:44 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 Jun 2026, 23:43 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 Jun 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 Jun 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 Jun 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 Jun 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 Jun 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 Jun 2026, 20:51 UTC

Earnings

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 Jun 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 Jun 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Jun 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 Jun 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 Jun 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 Jun 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 Jun 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 Jun 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 Jun 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 Jun 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 Jun 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 Jun 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 Jun 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 Jun 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 Jun 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 Jun 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Jun 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 Jun 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 Jun 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Peer Comparison

Price change

10X Genomics Inc (Class A) Forecast

Price Target

By TipRanks

-19.91% downside

12 Months Forecast

Average 24.5 USD -19.91%

High 32 USD

Low 20 USD

Based on 10 Wall Street analysts offering 12 month price targets for10X Genomics Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to 10X Genomics Inc (Class A) - Dist in the past 3 months.

Sentiment

By Acuity

153 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.